Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers.
about
The therapeutic profile of rolipram, PDE target and mechanism of action as a neuroprotectant following spinal cord injuryPDE4 inhibitors: current statusPhosphodiesterases maintain signaling fidelity via compartmentalization of cyclic nucleotidesCystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis.Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.ABCD of the phosphodiesterase family: interaction and differential activity in COPDRoflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide.p75 neurotrophin receptor regulates tissue fibrosis through inhibition of plasminogen activation via a PDE4/cAMP/PKA pathway.Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.Phosphodiesterase inhibitors.Inhibition of PDE4B suppresses inflammation by increasing expression of the deubiquitinase CYLD.Attenuation of TNF production and experimentally induced inflammation by PDE4 inhibitor rolipram is mediated by MAPK phosphatase-1.DISC1-ATF4 transcriptional repression complex: dual regulation of the cAMP-PDE4 cascade by DISC1.Future therapeutic treatment of COPD: struggle between oxidants and cytokinesCompartmentalized PDE4A5 Signaling Impairs Hippocampal Synaptic Plasticity and Long-Term Memory.Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease.Targeting lung inflammation: novel therapies for the treatment of COPD.Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.Phosphodiesterase-4 inhibitor therapy for lung diseases.Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases.The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease.Inhibition of phosphodiesterase-4 (PDE4) activity triggers luminal apoptosis and AKT dephosphorylation in a 3-D colonic-crypt model.Interaction between LIS1 and PDE4, and its role in cytoplasmic dynein functionRoflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro.Cyclic nucleotide phosphodiesterase isoforms in human basophils and mast cells.Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis.Polymorphisms in PDE4D are associated with a risk of COPD in non-emphysematous Koreans.Epac Function and cAMP Scaffolds in the Heart and Lung.
P2860
Q21089854-FACF2B42-851F-4904-9030-3E720E379834Q24651926-790B4AA5-2574-45E9-AE0D-9536FE8E98FEQ26860508-EEAD23F8-97F7-458A-B945-BB04EFCB3459Q33799668-13A89FDE-39F0-40B5-A891-A2DCC44E6757Q34091087-4E96738E-A58D-4BEA-B3CC-4D5F920D9B1CQ34961511-D33B235C-4AE4-4C5C-A8AC-7E37B24E23AEQ36025380-361D994C-801F-4140-BB13-008CE81A0811Q36118647-19CB1B4E-C03F-47E2-9710-D387AF1938CCQ36334968-FAFC9A27-F0FD-47A4-BEED-ED834D2100FBQ36364429-7074F6BA-C865-41AB-BBF2-49A02FE3386AQ36815462-A6F40ABB-5505-4B89-905D-293D3E73C2A2Q37046760-A38162C1-0B8F-4B2C-98F7-224CE32BF5A8Q37061724-7428478D-DF60-4F0A-B7B7-82119D8FD7AAQ37071004-C6A4FEA0-D73B-4EB1-B7AC-5DFBC2086208Q37198415-59CB9BA4-92C9-46D0-A2AA-6A9341A582CAQ37332621-9FE90A50-A6C8-4238-BF7C-6ABA7D4112E9Q37578310-57C13CFB-E56F-44BB-BD7A-C61E49A070E1Q37947681-70B5FF2B-B0EC-4A4F-8B99-CDE1BC66D150Q38105165-AB9C1636-7BC3-454E-85F9-C5B0934F669AQ38187182-D3EEB42E-71FC-4213-894C-495EC1A725A7Q38832398-98D1B1C6-3C13-4617-9699-F166BD772177Q39308493-76241CE0-67CB-4578-9128-4A5D495C74ACQ39528889-E043523B-288D-4BFC-AB62-5180F5F40CBEQ40024513-58C92C1C-E5CD-46BE-80E6-AA701A457423Q40092926-B7897FFF-D0AE-4F49-B465-F562BD061C0AQ42663487-8F788443-71F1-4436-B56D-D661BBF26EB9Q45071140-614A7C34-2609-4EBC-A8CF-87426EE66AD0Q48104933-7ABBBCC2-80D8-467D-8D17-A2C6DD7186D8
P2860
Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Differential expression of PDE ...... without COPD, and nonsmokers.
@en
Differential expression of PDE ...... without COPD, and nonsmokers.
@nl
type
label
Differential expression of PDE ...... without COPD, and nonsmokers.
@en
Differential expression of PDE ...... without COPD, and nonsmokers.
@nl
prefLabel
Differential expression of PDE ...... without COPD, and nonsmokers.
@en
Differential expression of PDE ...... without COPD, and nonsmokers.
@nl
P2093
P2860
P1476
Differential expression of PDE ...... without COPD, and nonsmokers.
@en
P2093
George S Baillie
Gino Van Heeke
Malcolm C Shepherd
Rachael Barber
Reinhard Bergmann
Ruth Sepper
P2860
P304
P356
10.1152/AJPLUNG.00384.2003
P577
2004-03-26T00:00:00Z